Novanta/$NOVT
1D1W1MYTD1Y5YMAX
Capital at risk
About Novanta
Novanta Inc supplies core technology solutions to medical, life science, and advanced industrial OEMs, leveraging proprietary expertise in precision medicine, precision manufacturing, robotics and automation, and advanced surgery. It has two segments: Automation Enabling Technologies and Medical Solutions. Automation Enabling Technologies, which generates the majority of revenue, provides laser beam steering and scanning solutions, laser sources, and robotic and precision motion technologies. The Medical Solutions segment provides medical-grade technologies, including medical insufflators, endoscopic pumps, and integrated operating room technologies. The company operates in the United States, Germany, and other markets, with revenue generated from the United States.
- Ticker
- $NOVT
- Sector
- Digital Hardware
- Primary listing
- NASDAQ
- Employees
- 3,000
- Headquarters
- Bedford, United States
- Website
- www.novanta.com
Novanta Metrics
BasicAdvanced
$5.6B
94.36
$1.58
1.68
-
Price and volume
Market cap
$5.6B
Beta
1.68
52-week high
$176.38
52-week low
$98.27
Average daily volume
348K
Financial strength
Current ratio
4.569
Quick ratio
3.65
Long term debt to equity
0.143
Total debt to equity
0.169
Interest coverage (TTM)
9.21%
Profitability
EBITDA (TTM)
180.952
Gross margin (TTM)
44.54%
Net profit margin (TTM)
6.00%
Operating margin (TTM)
11.59%
Effective tax rate (TTM)
22.49%
Revenue per employee (TTM)
$340,000
Management effectiveness
Return on assets (TTM)
4.09%
Return on equity (TTM)
5.11%
Valuation
Price to earnings (TTM)
94.356
Price to revenue (TTM)
5.644
Price to book
3.49
Price to tangible book (TTM)
6.93
Price to free cash flow (TTM)
50.855
Free cash flow yield (TTM)
1.97%
Free cash flow per share (TTM)
2.935
Growth
Revenue change (TTM)
7.61%
Earnings per share change (TTM)
-6.39%
3-year revenue growth (CAGR)
4.98%
10-year revenue growth (CAGR)
10.76%
3-year earnings per share growth (CAGR)
-9.59%
10-year earnings per share growth (CAGR)
11.19%
What the Analysts think about Novanta
Analyst ratings (Buy, Hold, Sell) for Novanta stock.
Analyst projections of the future price of Novanta stock.
Bulls say / Bears say
Novanta’s second-quarter organic revenue rose 9.3%, while adjusted EBITDA grew 16.4% and adjusted gross margin improved by one percentage point. That combination points to stronger demand alongside improving profitability. (Financial Post)
Bookings were up 18% year to date and backlog rose 11%, while revenue from new products grew more than 50% in the quarter. This gives Novanta a stronger base for continued growth in areas such as robotics and semiconductors. (The Motley Fool)
Riverpoint Medical roughly doubles recurring medical consumables to about a quarter of sales and lifts medical-market exposure to around 60%. Novanta says the deal should add to growth and profitability, and its updated 2026 revenue outlook is $1.13–$1.14 billion. (Financial Post)
Factory transition, logistics and tariff costs remain a drag, and management said pricing surcharges are not expected to offset all tariff increases. These pressures could limit the benefit of Novanta’s operational improvements. (The Motley Fool)
Riverpoint is a large acquisition whose contribution is built into Novanta’s raised outlook, making delivery dependent in part on successful integration and growth from the acquired business. Any shortfall could make the new targets harder to achieve. (Seeking Alpha, Simply Wall St)
Management said parts of the life-sciences market are commoditising and declining in the near term, and expects that business to return to growth only in late 2027. That leaves one part of the portfolio facing a prolonged recovery. (The Motley Fool)
Data summarised monthly by Lightyear AI. Last updated on 2 Oct 2026.
Novanta Financial Performance
Revenues and expenses
Novanta Earnings Performance
Company profitability
Upcoming events
No upcoming events
Novanta News
AllArticlesVideos
Funds containing Novanta
AllUSDEURGBP
Fund name | Fund size | $NOVT weighting |
|---|---|---|
iShares Automation & Robotics$RBOT | $5.2B | 0.26% |
iShares Automation & Robotics€2B76 | €4.5B | 0.26% |
iShares Automation & Robotics£RBTX | £3.8B | 0.26% |
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.17% |
SPDR Russell 2000 US Small Cap£R2SC | £4.1B | 0.17% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.